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In a hamster model of Chagas disease, Pimentel et al. (1)
recently found that 1) carvedilol decreased mortality in the
acute, but not in the chronic stage and 2) in the chronic
stage, carvedilol neither changed the left ventricular
diameter and/or function, nor attenuated changes in the
resting electrocardiogram (ECG), nor decreased the myo-
cardial collagen content.
In contrast, we did not observe a decrease in the mortality
rate of rats that were infected with Trypanosoma cruzi and
then received metoprolol to treat the ensuing acute Chagas
disease (2). Conceivably, both the animal model and the T.
cruzi strain might account for this disparity. Furthermore,
we found that chronic metoprolol administration reversed
the ECG abnormalities in the T. cruzi-infected rats at the
chronic stage of the disease. Left axis deviations and
intraventricular conduction delays have been observed in
almost half of rats chronically infected with T. cruzi, which
we believe supports the theory that the different animal
models used in the two studies were responsible for the
different results.
Pimentel et al. (1) did not observe any effects of the
chronic use of carvedilol on myocardial function and left
ventricular remodeling in their hamster model of chronic
Chagas heart disease. Although there are no other studies
for comparison, we agree with the assertion of Pimentel et al.
(1) that intense myocarditis, extensive myocardial fibrosis,
and sympathetic denervation may have overshadowed the
beneficial effects of the beta blocker therapy in this animal
model.
Our message is that the absence of a beneficial effect of
carvedilol use in a hamster model should not preclude the
use of beta blockers in Chagas disease patients, particularly
in the following two clinical settings. First, beta blockers
may be appropriate for patients with chronic systolic heart
failure because the activation of the autonomic nervous
system in these patients is similar to that observed in heart
failure patients without Chagas disease (3) and because beta
blocker therapy has produced good preliminary results in
this group of patients (4-7). Second, beta blocker therapy
may be suitable for patients receiving implantable cardio-
verter-defibrillator therapy for the secondary prevention of
sudden cardiac death due to the high recurrence rate of
malignant arrhythmias in this patient group in the absence
of beta blocker therapy (8).
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